Compare VSTM & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSTM | SABR |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.7M | 489.7M |
| IPO Year | 2011 | 2014 |
| Metric | VSTM | SABR |
|---|---|---|
| Price | $6.39 | $1.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $14.50 | $3.70 |
| AVG Volume (30 Days) | 1.4M | ★ 17.7M |
| Earning Date | 05-18-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.49 | ★ 283.56 |
| EPS | N/A | ★ 1.34 |
| Revenue | $30,914,000.00 | ★ $3,866,956,000.00 |
| Revenue This Year | $201.42 | $7.40 |
| Revenue Next Year | $263.25 | $3.26 |
| P/E Ratio | ★ N/A | $1.18 |
| Revenue Growth | ★ 209.14 | 7.46 |
| 52 Week Low | $4.01 | $0.81 |
| 52 Week High | $11.25 | $3.63 |
| Indicator | VSTM | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 59.97 |
| Support Level | $6.35 | $1.63 |
| Resistance Level | $6.91 | $1.70 |
| Average True Range (ATR) | 0.32 | 0.21 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 87.25 | 69.62 |
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.